Welcome to our dedicated page for Inspira Technologies Oxy Bhn SEC filings (Ticker: IINN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. Inspira files Form 6-K current reports under the Securities Exchange Act of 1934, along with registration statements on Form F-3 and Form S-8 referenced in those reports. These filings document key events in the company’s development as a commercial-stage medical device and diagnostics business focused on respiratory support and blood monitoring.
Recent Form 6-K reports describe transactions such as a registered direct offering of ordinary shares and a Standby Equity Purchase Agreement that together outline Inspira’s equity financing tools. Other 6-Ks incorporate press releases on clinical and regulatory milestones, including progress with the HYLA non-invasive blood sensor, regulatory steps for the INSPIRA ART100 system in the United Arab Emirates, and financial results and business updates. Filings also cover shareholder meeting materials, board and executive changes, and adjustments to sales agreements for ordinary shares.
Through this page, users can review Inspira’s SEC-reported information on capital structure, financing arrangements, and material operational updates. Stock Titan’s tools can surface new 6-K submissions in real time and help summarize their contents, allowing readers to quickly understand how each filing relates to topics such as product commercialization, clinical studies, or corporate governance. For deeper analysis, investors can examine attachments referenced in the 6-Ks, including financial statements, management’s discussion and analysis, and opinions related to securities offerings.
Inspira Technologies Oxy B.H.N. Ltd. (IINN) furnished a Form 6-K announcing a press release titled “Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission.”
The Company states that the first three and fifth paragraphs and the “Forward-Looking Statements” section of the press release are incorporated by reference into its Registration Statements on Form F-3 (Nos. 333-266748, 333-284308, 333-289324) and Form S-8 (Nos. 333-259057, 333-277980, 333-285565, 333-290162).
Inspira Technologies Oxy B.H.N. Ltd. (IINN) furnished a Form 6-K announcing a press release titled “Inspira Technologies Nears Final Regulatory Clearance for the ART100 in the UAE, Accelerating Gulf Region Expansion.” The press release is attached as Exhibit 99.1.
The filing states that the first, second, and fourth paragraphs, along with the “Forward-Looking Statements” section of the press release, are incorporated by reference into the company’s Registration Statements on Form F-3 and Form S-8, to be a part thereof from the date of this report, to the extent not superseded.
Inspira Technologies (IINN) furnished a Form 6-K announcing a press release titled “Inspira and Bites Form Strategic Alliance to Embed AI as a Core Standard Across Inspira’s Global Ecosystem.” The filing notes that the first four paragraphs and the “Forward-Looking Statements” section of the release are incorporated by reference into the company’s existing registration statements on Form F-3 and Form S-8, effective upon submission.
Inspira Technologies Oxy B.H.N. Ltd. (IINN) filed a Form 6-K announcing leadership additions. On October 21, 2025, the company furnished a press release titled “Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm.”
The first three paragraphs and the “Forward-Looking Statements” section of the release are incorporated by reference into Inspira’s Registration Statements on Forms F-3 and S-8, effective from the submission date, to the extent not superseded by later filings.
Inspira Technologies Oxy B.H.N. Ltd. filed a Form 6-K that packages its first half 2025 financial communication. The report furnishes a press release titled “Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update,” unaudited interim condensed consolidated financial statements as of June 30, 2025, and management’s discussion and analysis for the six months ended June 30, 2025.
These materials are also incorporated by reference into the company’s existing Form F-3 and Form S-8 registration statements, meaning the mid‑2025 financial information and business update become part of the disclosure record supporting those securities offerings.
Inspira Technologies Oxy B.H.N. Ltd. submitted a Form 6-K that incorporates by reference previously filed registration statements and furnishes a press release dated September 18, 2025. The press release announces that Inspira will unveil its HYLA™ real-time blood sensor at the U.S. ELSO conference and states the device has 97.35% accuracy confirmed. The filing is signed by Chief Executive Officer Dagi Ben-Noon. The document provides an event announcement and a specific accuracy figure for the product but does not include financial results, commercialization details, regulatory approvals, or timelines.
IINN is amending its at-the-market offering program with A.G.P./Alliance Global Partners to increase the maximum aggregate offering price of its ordinary shares that may be sold under the existing sales agreement from
The company has already sold ordinary shares for an aggregate of approximately
Inspira Technologies Oxy B.H.N. Ltd. filed a report noting it has increased the maximum aggregate offering price of its ordinary shares that may be issued under its existing Sales Agreement with A.G.P./Alliance Global Partners from $7,117,720 to $9,985,579. This agreement allows the company to sell ordinary shares from time to time, and the change expands the total dollar amount of shares that can be issued through this program.
The company also filed a legal opinion from Sullivan & Worcester Tel-Aviv (Har-Even & Co.) confirming the legality of issuing and selling these ordinary shares under the Sales Agreement. This report is incorporated by reference into multiple existing registration statements on Form F-3 and Form S-8, meaning those registration statements now include this updated at-the-market capacity.